CatalystWireBeta

Ixico

IXI · AIM · Health Care · mcap £17m · 7.8p

Beta Briefing, track record and bull & bear case are not ready for Ixico yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 37 companies are already wired into a briefing: browse them.

Key announcements Monitoring checked today, 08:05

DateTypeAnnouncementDay
01 Oct 26 IXICO present PD research at radiology conference
IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference
+0.0%
27 Jul 26 Share option award
27 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today a
+0.0%
13 Jul 26 HD Industry Update
13 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, notes t
−10.8%
07 Jul 26 Trading update Trading Update
Revenue anticipated to be ahead of expectations for the year ending 30 September 2026
+12.0%
08 Jun 26 Scientific advisors & partners update
IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER'S AND PARKINSON'S DISEASE
+0.0%
22 May 26 Company presentation at Mello 2026
22 May 2026, IXICO plc (AIM: IXI) - London, UK.
+0.0%
21 May 26 Contract win and contract extension
Alzheimer's contract win and Phase 2 clinical trial contract extension with total value of £1.3 million
+1.8%
19 May 26 Results Half-year Results
Interim results for six months ending 31 March 2026
+27.8%
12 May 26 IXICO Updates AI Neuroimaging Platform
IXICO RELEASES LATEST VERSION OF AI-DRIVEN NEUROIMAGING TECHNOLOGY PLATFORM
+1.9%
21 Apr 26 Trading update Trading Update
Half-year Trading update and Notice of Interim Results
+0.0%
16 Apr 26 Result of GM and Update on Issue of Equity
Result of General Meeting and Update on Issue of Equity
−3.4%
07 Apr 26 Fundraise Result of Retail Offer
IXICO is pleased to announce that the Retail Offer launched on 31 March 2026 has now closed, raising gross proceeds of £30,320.
−1.6%
31 Mar 26 Fundraise Retail Offer
IXICO is pleased to announce a retail offer via the BookBuild Platform (the "Retail Offer") of up to 6,250,000 new ordinary shares ("Ordinary Shares") of £0.01 each in the capital of the Company (the "Retail Offer Shares
+0.0%
31 Mar 26 Fundraise Placings and Subscription
THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY.
+0.0%
26 Mar 26 Collaboration with Medidata
IXICO and Medidata collaborate to create an advanced neuroimaging clinical trials platform
+1.0%
26 Feb 26 Validation of Neuroimaging Technology Platform
26 February 2026, IXICO plc (AIM: IXI) - London, UK.
+0.0%
12 Feb 26 C.£1.5 million Contract Extension
The following amendment has been made to the "c.£1.5 million Contract Extension" announcement released at 07:00 on 12 February 2026:
−14.6%
12 Feb 26 C.£1.5 million Contract Extension
c.£1.5 million contract extension on global Phase 2 clinical trial
−14.6%
05 Feb 26 Appointment of Chief Commercial Officer
IXICO appoints Chief Commercial Officer to accelerate business development activity and broaden US footprint
+0.0%
23 Jan 26 Result of AGM
IXICO plc (AIM: IXI), a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that all resolutions pu
−4.3%
09 Dec 25 Share option award
9 December 2025 IXICO plc (AIM: IXI) - London, UK.
+14.0%
09 Dec 25 Results Financial Results for year ended 30 September 2025
Financial Results for year ended 30 September 2025 and Notice of AGM
+14.0%
01 Dec 25 Operational Update
IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer's Disease and vascular experts
+0.0%
27 Nov 25 Notice of 2025 Full Year Results and IMC
Notice of 2025 Full Year Results and Investor Presentation
+0.0%
17 Nov 25 Clinical Trial Contract Win
Global Phase 3 clinical trial contract win worth over £3.5 million
+4.7%
03 Nov 25 Capital Markets Day Presentation and Video
03 November 2025 IXICO plc (AIM: IXI) - London, UK.
+2.2%
16 Oct 25 Trading update Trading Update
Trading update for the year ended 30 September 2025
−2.0%
15 Oct 25 New contract win and contract extension
contract extension worth a total of £1.2 million.
+4.2%

Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note